



October 18, 2024

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Symbol: LUPIN

Scrip Code: Equity - 500257

Ref: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Sub: Appointment of Senior Management Personnel by WOS

Dear Sir/Madam,

We are pleased to inform you that the Company's Wholly Owned Subsidiary Lupin Management, Inc., USA has appointed Mr. Claus Jepsen as 'President, Global Specialty'. Mr. Jepsen shall accelerate Lupin's plans to evolve its specialty brand business and to attain its mission to bring access to innovative medicines for patients and communities it serves.

Disclosure in compliance with Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in respect of change in Senior Management is enclosed as **Annexure - 'A'**.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY
(ACS -15754)**

Encl: - Annexure - 'A'

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com



ANNEXURE - 'A'

Particulars as per Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sl. No.	Particulars	Description
1.	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise.	Appointment of Mr. Claus Jepsen as Senior Management Personnel to be designated as 'President, Global Specialty' by Lupin Management, Inc., USA, Wholly Owned Subsidiary of the Company.
2.	date of appointment/re-appointment/cessation & terms of appointment/re-appointment.	October 18, 2024, and is not for a fixed term.
3.	brief profile.	<p>Mr. Jepsen has over 30 years of experience in the pharmaceutical industry, leading commercial strategy, portfolio choices and launch planning across Europe, Asia, and the United States.</p> <p>Mr. Jepsen has worked with Takeda Pharmaceuticals, where he led the Global Product Strategy for Rare Diseases. In this role, he spearheaded major initiatives aimed at bringing new treatments to patients with rare and often underserved medical needs. Prior to Takeda, he was at GSK and served in many roles including country general manager in Asia and led global franchise management in therapeutic areas such as Immunology, Respiratory and Neurology. Mr. Jepsen has launched major brands like Ellipta in the U.S., and has led brands such as Advair and Seretide in both Europe and U.S.</p>
4.	disclosure of relationships between directors.	None

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com